# HIV Vaccine Trials Network Laboratory Center - B-Cell and Molecular Assay Multi-year Supplement

> **NIH NIH UM1** · FRED HUTCHINSON CANCER CENTER · 2024 · $3,287,548

## Abstract

Abstract
Accelerating B Cell and Antibody Molecular, Functional and Structural Analysis
 in Sequential bnAb-inducing Env Immunogen Clinical Trials
 Development of an effective HIV vaccine is essential for achieving long-term immunity to prevent new HIV
infections globally. A successful HIV vaccine regimen will likely need to induce potent broad neutralizing
antibodies (bnAbs) to contemporary circulating viral strains. New HIV Env immunogen designs, guided by
knowledge of bnAb interactions with envelope epitopes and their B cell clonal lineage development in natural
HIV infection, have entered first in human studies in the HVTN. These phase 1 “discovery” trials rely on more
efficient, near real-time molecular, functional, and structural analyses of B cell and antibody responses. To meet
this expectation, the HVTN Laboratory Center proposes to continue expansion and improvement of laboratory
and analytical capacity that can accelerate iterative evaluation of bnAb-inducing vaccine candidates. The
supplemental funds for the HVTN Laboratory make it possible to fully access evolving immunologic, molecular,
and structural technology, which deepens our laboratory analyses and increases throughput of data generation
and interpretation. To accomplish this, we will sustain the employment of additional dedicated trained staff and
equipment to increase laboratory throughput of B cell repertoire, antibody binding with epitope mapping,
neutralization, and antibody structural analyses. These funds will continue to enable efficient laboratory
operations and integration of the scientific partnerships between key investigators at Fred Hutch, Duke
University, and the Scripps Research Institute.

## Key facts

- **NIH application ID:** 11083981
- **Project number:** 3UM1AI068618-19S1
- **Recipient organization:** FRED HUTCHINSON CANCER CENTER
- **Principal Investigator:** Margaret Juliana McElrath
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $3,287,548
- **Award type:** 3
- **Project period:** 2024-08-16 → 2026-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11083981

## Citation

> US National Institutes of Health, RePORTER application 11083981, HIV Vaccine Trials Network Laboratory Center - B-Cell and Molecular Assay Multi-year Supplement (3UM1AI068618-19S1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/11083981. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*